Vaccine developer Vaxcyte's deal for long-term US commercial manufacturing in Thermo Fisher's North Carolina plant for their pneumococcal conjugate vaccines (PCVs). Show's their betting on recieving FDA approval for their VAX-31 candidate which is currently in phase III in adults and phase II in infants.

Part of the "onshoring" trend moving more manufacturing to US facilities, probably due to both pandemic response and the current political climate. Overall imo CDMOs are holding more power in this biotech climate.